Use of Antiherpes Drugs and the Risk of Kaposi's Sarcoma: Data from the Multicenter AIDS Cohort Study
To determine if use of antiherpes drugs protects against the development of AIDS-associated Kaposi's sarcoma (KS), data from 935 homosexual men with AIDS from the Multicenter AIDS Cohort Study were analyzed. In nested case-control analysis, neither acyclovir use for human immunodeficiency virus...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1996-06, Vol.173 (6), p.1477-1480 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1480 |
|---|---|
| container_issue | 6 |
| container_start_page | 1477 |
| container_title | The Journal of infectious diseases |
| container_volume | 173 |
| creator | Glesby, Marshall J. Hoover, Donald R. Weng, Shigui Graham, Neil M. H. Phair, John P. Detels, Roger Ho, Monto Saah, Alfred J. |
| description | To determine if use of antiherpes drugs protects against the development of AIDS-associated Kaposi's sarcoma (KS), data from 935 homosexual men with AIDS from the Multicenter AIDS Cohort Study were analyzed. In nested case-control analysis, neither acyclovir use for human immunodeficiency virus infection (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.56–1.26; P = .39) nor acyclovir use for any indication (OR, 1.02; 95% CI, 0.76–1.38; P = .89) was associated with a reduced risk of KS as initial AIDS diagnosis. In longitudinal analysis, acyclovir was also not protective against developing KS as a late manifestation of AIDS (after initial non-KS AIDS diagnosis). Among men with cytomegalovirus disease, ganciclovir use (relative risk [RR], 0.56; 95% CI, 0.22–1.44; P = .23) and foscarnet use (RR, 0.40; 95% CI, 0.051–3.10; P = .38) were associated (although not significantly) with a reduced risk of KS. Thus, acyclovir use does not appear to reduce the risk of KS, but further study of other antiherpes drugs such as ganciclovir and foscarnet is warranted. |
| doi_str_mv | 10.1093/infdis/173.6.1477 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_78031273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30128162</jstor_id><sourcerecordid>30128162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-f783ba37a0737047494a35b628ea30264e16f69cb5803735e515d260f07d282c3</originalsourceid><addsrcrecordid>eNqFkc1uEzEUhS0EKiHwACyQLIRgNal_xn_dhYTSqkGIphWIjeV4PGTSmXGwPRJ9-zpNKIgNKy--7x5d3wPAS4wmGCl63PR11cRjLOiET3ApxCMwwoyKgnNMH4MRQoQUWCr1FDyLcYMQKikXR-BI8lISUo6Au44O-hpO-9SsXdi6COdh-BGh6SuY1g5eNvFmJ1yYrY_NuwiXJljfmRM4N8nAOvju3vs0tKmxrk8uwOn5fAlnfu1Dgss0VLfPwZPatNG9OLxjcH364Wp2Viw-fzyfTReFLSVPRS0kXRkqDBJUoFKUqjSUrTiRzlBEeOkwr7myKyYRFZQ5hllFOKqRqIgklo7B233uNvifg4tJd020rm1N7_wQtchzmAj6XxEzpvI9URZf_yNu_BD6_AlNCFVY4bzrGOC9ZIOPMbhab0PTmXCrMdK7ovS-KJ2L0lzvisozrw7Bw6pz1cPEoZnM3xy4ida0dTC9zQm_NYoUloj8idnE5MNfGBOJ-Y4Xe97E5H49cBNuNM9HZvrs23d9tfjy_iu5XGhF7wABPLIM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223919107</pqid></control><display><type>article</type><title>Use of Antiherpes Drugs and the Risk of Kaposi's Sarcoma: Data from the Multicenter AIDS Cohort Study</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>JSTOR</source><creator>Glesby, Marshall J. ; Hoover, Donald R. ; Weng, Shigui ; Graham, Neil M. H. ; Phair, John P. ; Detels, Roger ; Ho, Monto ; Saah, Alfred J.</creator><creatorcontrib>Glesby, Marshall J. ; Hoover, Donald R. ; Weng, Shigui ; Graham, Neil M. H. ; Phair, John P. ; Detels, Roger ; Ho, Monto ; Saah, Alfred J.</creatorcontrib><description>To determine if use of antiherpes drugs protects against the development of AIDS-associated Kaposi's sarcoma (KS), data from 935 homosexual men with AIDS from the Multicenter AIDS Cohort Study were analyzed. In nested case-control analysis, neither acyclovir use for human immunodeficiency virus infection (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.56–1.26; P = .39) nor acyclovir use for any indication (OR, 1.02; 95% CI, 0.76–1.38; P = .89) was associated with a reduced risk of KS as initial AIDS diagnosis. In longitudinal analysis, acyclovir was also not protective against developing KS as a late manifestation of AIDS (after initial non-KS AIDS diagnosis). Among men with cytomegalovirus disease, ganciclovir use (relative risk [RR], 0.56; 95% CI, 0.22–1.44; P = .23) and foscarnet use (RR, 0.40; 95% CI, 0.051–3.10; P = .38) were associated (although not significantly) with a reduced risk of KS. Thus, acyclovir use does not appear to reduce the risk of KS, but further study of other antiherpes drugs such as ganciclovir and foscarnet is warranted.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/173.6.1477</identifier><identifier>PMID: 8648224</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Acyclovir - therapeutic use ; AIDS ; AIDS-Related Opportunistic Infections - drug therapy ; AIDS-Related Opportunistic Infections - prevention & control ; AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Bisexuality ; Case-Control Studies ; Cohort studies ; Concise Communication ; Cytomegalovirus ; Delayed diagnosis ; Disease models ; Disease risk ; Foscarnet - therapeutic use ; Ganciclovir - therapeutic use ; Herpesviridae ; Herpesviridae Infections - drug therapy ; Herpesviridae Infections - prevention & control ; HIV ; Homosexuality, Male ; Humans ; Kaposi sarcoma ; Longitudinal Studies ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Public health ; Risk ; Sarcoma, Kaposi - drug therapy ; Sarcoma, Kaposi - prevention & control</subject><ispartof>The Journal of infectious diseases, 1996-06, Vol.173 (6), p.1477-1480</ispartof><rights>Copyright 1996 The University of Chicago</rights><rights>1996 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Jun 1996</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-f783ba37a0737047494a35b628ea30264e16f69cb5803735e515d260f07d282c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30128162$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30128162$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>315,782,786,805,27931,27932,58024,58257</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3091802$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8648224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glesby, Marshall J.</creatorcontrib><creatorcontrib>Hoover, Donald R.</creatorcontrib><creatorcontrib>Weng, Shigui</creatorcontrib><creatorcontrib>Graham, Neil M. H.</creatorcontrib><creatorcontrib>Phair, John P.</creatorcontrib><creatorcontrib>Detels, Roger</creatorcontrib><creatorcontrib>Ho, Monto</creatorcontrib><creatorcontrib>Saah, Alfred J.</creatorcontrib><title>Use of Antiherpes Drugs and the Risk of Kaposi's Sarcoma: Data from the Multicenter AIDS Cohort Study</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>To determine if use of antiherpes drugs protects against the development of AIDS-associated Kaposi's sarcoma (KS), data from 935 homosexual men with AIDS from the Multicenter AIDS Cohort Study were analyzed. In nested case-control analysis, neither acyclovir use for human immunodeficiency virus infection (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.56–1.26; P = .39) nor acyclovir use for any indication (OR, 1.02; 95% CI, 0.76–1.38; P = .89) was associated with a reduced risk of KS as initial AIDS diagnosis. In longitudinal analysis, acyclovir was also not protective against developing KS as a late manifestation of AIDS (after initial non-KS AIDS diagnosis). Among men with cytomegalovirus disease, ganciclovir use (relative risk [RR], 0.56; 95% CI, 0.22–1.44; P = .23) and foscarnet use (RR, 0.40; 95% CI, 0.051–3.10; P = .38) were associated (although not significantly) with a reduced risk of KS. Thus, acyclovir use does not appear to reduce the risk of KS, but further study of other antiherpes drugs such as ganciclovir and foscarnet is warranted.</description><subject>Acyclovir - therapeutic use</subject><subject>AIDS</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>AIDS-Related Opportunistic Infections - prevention & control</subject><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bisexuality</subject><subject>Case-Control Studies</subject><subject>Cohort studies</subject><subject>Concise Communication</subject><subject>Cytomegalovirus</subject><subject>Delayed diagnosis</subject><subject>Disease models</subject><subject>Disease risk</subject><subject>Foscarnet - therapeutic use</subject><subject>Ganciclovir - therapeutic use</subject><subject>Herpesviridae</subject><subject>Herpesviridae Infections - drug therapy</subject><subject>Herpesviridae Infections - prevention & control</subject><subject>HIV</subject><subject>Homosexuality, Male</subject><subject>Humans</subject><subject>Kaposi sarcoma</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Public health</subject><subject>Risk</subject><subject>Sarcoma, Kaposi - drug therapy</subject><subject>Sarcoma, Kaposi - prevention & control</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1uEzEUhS0EKiHwACyQLIRgNal_xn_dhYTSqkGIphWIjeV4PGTSmXGwPRJ9-zpNKIgNKy--7x5d3wPAS4wmGCl63PR11cRjLOiET3ApxCMwwoyKgnNMH4MRQoQUWCr1FDyLcYMQKikXR-BI8lISUo6Au44O-hpO-9SsXdi6COdh-BGh6SuY1g5eNvFmJ1yYrY_NuwiXJljfmRM4N8nAOvju3vs0tKmxrk8uwOn5fAlnfu1Dgss0VLfPwZPatNG9OLxjcH364Wp2Viw-fzyfTReFLSVPRS0kXRkqDBJUoFKUqjSUrTiRzlBEeOkwr7myKyYRFZQ5hllFOKqRqIgklo7B233uNvifg4tJd020rm1N7_wQtchzmAj6XxEzpvI9URZf_yNu_BD6_AlNCFVY4bzrGOC9ZIOPMbhab0PTmXCrMdK7ovS-KJ2L0lzvisozrw7Bw6pz1cPEoZnM3xy4ida0dTC9zQm_NYoUloj8idnE5MNfGBOJ-Y4Xe97E5H49cBNuNM9HZvrs23d9tfjy_iu5XGhF7wABPLIM</recordid><startdate>19960601</startdate><enddate>19960601</enddate><creator>Glesby, Marshall J.</creator><creator>Hoover, Donald R.</creator><creator>Weng, Shigui</creator><creator>Graham, Neil M. H.</creator><creator>Phair, John P.</creator><creator>Detels, Roger</creator><creator>Ho, Monto</creator><creator>Saah, Alfred J.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19960601</creationdate><title>Use of Antiherpes Drugs and the Risk of Kaposi's Sarcoma: Data from the Multicenter AIDS Cohort Study</title><author>Glesby, Marshall J. ; Hoover, Donald R. ; Weng, Shigui ; Graham, Neil M. H. ; Phair, John P. ; Detels, Roger ; Ho, Monto ; Saah, Alfred J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-f783ba37a0737047494a35b628ea30264e16f69cb5803735e515d260f07d282c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Acyclovir - therapeutic use</topic><topic>AIDS</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>AIDS-Related Opportunistic Infections - prevention & control</topic><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bisexuality</topic><topic>Case-Control Studies</topic><topic>Cohort studies</topic><topic>Concise Communication</topic><topic>Cytomegalovirus</topic><topic>Delayed diagnosis</topic><topic>Disease models</topic><topic>Disease risk</topic><topic>Foscarnet - therapeutic use</topic><topic>Ganciclovir - therapeutic use</topic><topic>Herpesviridae</topic><topic>Herpesviridae Infections - drug therapy</topic><topic>Herpesviridae Infections - prevention & control</topic><topic>HIV</topic><topic>Homosexuality, Male</topic><topic>Humans</topic><topic>Kaposi sarcoma</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Public health</topic><topic>Risk</topic><topic>Sarcoma, Kaposi - drug therapy</topic><topic>Sarcoma, Kaposi - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glesby, Marshall J.</creatorcontrib><creatorcontrib>Hoover, Donald R.</creatorcontrib><creatorcontrib>Weng, Shigui</creatorcontrib><creatorcontrib>Graham, Neil M. H.</creatorcontrib><creatorcontrib>Phair, John P.</creatorcontrib><creatorcontrib>Detels, Roger</creatorcontrib><creatorcontrib>Ho, Monto</creatorcontrib><creatorcontrib>Saah, Alfred J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glesby, Marshall J.</au><au>Hoover, Donald R.</au><au>Weng, Shigui</au><au>Graham, Neil M. H.</au><au>Phair, John P.</au><au>Detels, Roger</au><au>Ho, Monto</au><au>Saah, Alfred J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Antiherpes Drugs and the Risk of Kaposi's Sarcoma: Data from the Multicenter AIDS Cohort Study</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1996-06-01</date><risdate>1996</risdate><volume>173</volume><issue>6</issue><spage>1477</spage><epage>1480</epage><pages>1477-1480</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>To determine if use of antiherpes drugs protects against the development of AIDS-associated Kaposi's sarcoma (KS), data from 935 homosexual men with AIDS from the Multicenter AIDS Cohort Study were analyzed. In nested case-control analysis, neither acyclovir use for human immunodeficiency virus infection (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.56–1.26; P = .39) nor acyclovir use for any indication (OR, 1.02; 95% CI, 0.76–1.38; P = .89) was associated with a reduced risk of KS as initial AIDS diagnosis. In longitudinal analysis, acyclovir was also not protective against developing KS as a late manifestation of AIDS (after initial non-KS AIDS diagnosis). Among men with cytomegalovirus disease, ganciclovir use (relative risk [RR], 0.56; 95% CI, 0.22–1.44; P = .23) and foscarnet use (RR, 0.40; 95% CI, 0.051–3.10; P = .38) were associated (although not significantly) with a reduced risk of KS. Thus, acyclovir use does not appear to reduce the risk of KS, but further study of other antiherpes drugs such as ganciclovir and foscarnet is warranted.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>8648224</pmid><doi>10.1093/infdis/173.6.1477</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1996-06, Vol.173 (6), p.1477-1480 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78031273 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); JSTOR |
| subjects | Acyclovir - therapeutic use AIDS AIDS-Related Opportunistic Infections - drug therapy AIDS-Related Opportunistic Infections - prevention & control AIDS/HIV Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Biological and medical sciences Bisexuality Case-Control Studies Cohort studies Concise Communication Cytomegalovirus Delayed diagnosis Disease models Disease risk Foscarnet - therapeutic use Ganciclovir - therapeutic use Herpesviridae Herpesviridae Infections - drug therapy Herpesviridae Infections - prevention & control HIV Homosexuality, Male Humans Kaposi sarcoma Longitudinal Studies Male Medical sciences Pharmacology. Drug treatments Public health Risk Sarcoma, Kaposi - drug therapy Sarcoma, Kaposi - prevention & control |
| title | Use of Antiherpes Drugs and the Risk of Kaposi's Sarcoma: Data from the Multicenter AIDS Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T21%3A19%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Antiherpes%20Drugs%20and%20the%20Risk%20of%20Kaposi's%20Sarcoma:%20Data%20from%20the%20Multicenter%20AIDS%20Cohort%20Study&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Glesby,%20Marshall%20J.&rft.date=1996-06-01&rft.volume=173&rft.issue=6&rft.spage=1477&rft.epage=1480&rft.pages=1477-1480&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/173.6.1477&rft_dat=%3Cjstor_proqu%3E30128162%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223919107&rft_id=info:pmid/8648224&rft_jstor_id=30128162&rfr_iscdi=true |